Abstracts tagged "outcomes"

Abstract Number: 1299 • 2017 ACR/ARHP Annual Meeting
Patient-Reported Disease Activity and Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus and Rheumatoid Arthritis
Nathaniel Harris¹, Amanda M. Eudy² and Megan E. B. Clowse², ¹Duke University School of Medicine, Durham, NC, ²Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, NC
Background/Purpose: Patient-reported measures of disease activity may provide useful adjuncts to physician-reported measures in identifying pregnancies at greater risk for adverse pregnancy outcomes. Little is…
Abstract Number: 1317 • 2017 ACR/ARHP Annual Meeting
Obstetric Outcomes in Women with Rheumatoid Arthritis: Results from Nationwide Inpatient Sample Database 2003-2011
Shweta Kishore¹, Varun Mittal², Venkataraman Palabindala³, Shradha Ahuja³ and Vikas Majithia^1,4, ¹Division of Rheumatology, University of Mississippi, Jackson, MS, ²Division of Hematology and Oncology, Albert Einstein Healthcare Network, Philadelphia, PA, ³Division of Hospital Medicine, University of Mississippi, Jackson, MS, ⁴Jackson VA Medical Center and University of Mississippi, Jackson, MS
Background/Purpose: Fertility is reduced in patients with Rheumatoid Arthritis (RA) due to unknown cause. Few studies mostly involving single center cohorts have addressed pregnancy outcomes…
Abstract Number: 1391 • 2017 ACR/ARHP Annual Meeting
Ultrasound Response to Tocilizumab in Surgically Replaced Joints and Surgically Operated Joint Areas of Rheumatoid Arthritis Patients
Evan Choate¹, Gurjit S. Kaeley², Jenny Brook³, John Fitzgerald⁴, David Elashoff⁵ and Veena K. Ranganath⁶, ¹David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, ²Rheumatology, University of Florida College of Medicine, Jacksonville, Jacksonville, FL, ³Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁴David Geffen School of Medicine, Division of Rheumatology, Department of Internal Medicine, University of California, Los Angeles, Los Angeles, CA, ⁵David Geffen School of Medicine,, University of California, Los Angeles, Los Angeles, CA, ⁶Medicine/Rheumatology, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Rheumatoid Arthritis (RA) disease activity outcomes are used for treatment decisions (ie. DAS28-ESR). Surgically operated joints (SOJ) are assumed not to respond to therapy…
Abstract Number: 1392 • 2017 ACR/ARHP Annual Meeting
Effect Size Comparison of Ultrasound Measures in Rheumatoid Arthritis
Veena K. Ranganath¹, David Elashoff², Jenny Brook³, Ami Ben-Artzi⁴, Geraldine Navarro⁵, Lynnette Avedikian-Tatosyan⁶, George Karpouzas⁷, William Martin⁵, Tanaz A. Kermani⁵, Soo Choi⁵ and Gurjit S. Kaeley⁸, ¹Medicine/Rheumatology, University of California, Los Angeles, Los Angeles, CA, ²David Geffen School of Medicine,, University of California, Los Angeles, Los Angeles, CA, ³Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁴Medicine, Cedars, Beverly Hills, CA, ⁵Medicine, Division of Rheumatology, David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁶Healthcare Partners, Los Angeles, CA, ⁷Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ⁸Rheumatology, University of Florida College of Medicine, Jacksonville, Jacksonville, FL
Background/Purpose: Currently there are several outcome metrics used for the assessment and quantification of musculoskeletal (MSK) ultrasound inflammatory burden in rheumatoid arthritis (RA). This study…
Abstract Number: 1543 • 2017 ACR/ARHP Annual Meeting
Real-World Effectiveness of TNF Inhibition in Spondyloarthritis. Data from a Large Nationwide Prospective Cohort – the British Society for Rheumatology Biologics Register for Ankylosing Spondylitis
Gareth T. Jones¹, Andrew Keat², Ejaz Pathan³ and Gary J. Macfarlane¹, ¹Epidemiology Group, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, United Kingdom, ²Rheumatology., Northwick Park Hospital, London, United Kingdom, ³Department of Rheumatology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom
Background/Purpose: TNF inhibition has revolutionised the treatment of axial spondyloarthritis (AxSpA). Much of what we know about the use of these drugs comes from randomised…
Abstract Number: 1754 • 2017 ACR/ARHP Annual Meeting
Childhood- Vs. Adult-Onset ANCA-Associated Vasculitides: A Nested, Matched Case–Control Study from the French Vasculitis Study Group Registry
Michele Iudici¹, Christian Pagnoux², Pierre Quartier³, Mathias Büchler⁴, Ramiro Cevallos⁵, Pascal Cohen⁶, Claire de Moreuil⁷, Philippe Guilpain⁸, Alain Le Quellec⁸, Jacques Serratrice⁹, Benjamin Terrier⁶, Claire Le Jeunne⁶, Loïc Guillevin¹, Luc Mouthon¹⁰ and Xavier Puéchal for the French Vasculitis Study Group¹, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ²Mount Sinai Hospital, Toronto, ON, Canada, ³Necker-Enfants Malades Hospital, Paris, France, ⁴Tours, Tours, France, ⁵Strasbourg, Strasbourg, France, ⁶Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ⁷CHU de Brest, Brest, France, ⁸Montpellier, Montpellier, France, ⁹Marseille, Marseille, France, ¹⁰Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France ;Université Paris Descartes Sorbonne Paris, Paris, France
Background/Purpose: ANCA-associated vasculitides (AAVs) are potentially life-threatening diseases rarely observed in childhood. Whether AAVs in children (cAAVs) differ from adult-onset AAVs (aAAVs) is still not…
Abstract Number: 1801 • 2017 ACR/ARHP Annual Meeting
Quantifying Clinical and Economic Outcomes Associated with Chronic Corticosteroid Exposure in a US Population
J. Bradford Rice¹, Alan White¹, Andrea Lopez¹, Aneesha Wagh¹, Yimin Qin², Ghaith Mitri², Laura Bartels-Peculis², Gosia Ciepielewska² and Winnie Nelson³, ¹Analysis Group, Inc., Boston, MA, ²Mallinckrodt Pharmaceuticals, Hampton, NJ, ³Health Economics and Outcomes Research, Mallinckrodt Pharmaceuticals, Hampton, NJ
Background/Purpose: Corticosteroids (CS) are commonly used for rheumatologic conditions, and known to cause systemic adverse events (AEs), particularly when used at high doses for prolonged…
Abstract Number: 1957 • 2017 ACR/ARHP Annual Meeting
Impact of Maternal Systemic Autoimmune Rheumatic Diseases on Neonatal Outcomes: A Population-Level Analysis
Stephanie Keeling¹, Anamaria Savu² and Padmaja Kaul³, ¹Department of Medicine, University of Alberta, Division of Rheumatology, Edmonton, AB, Canada, ²Canadian Vigour Center, Edmonton, AB, Canada, ³Cardiology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: The impact of systemic autoimmune rheumatic diseases (SARDS) on peripartum outcomes is not well described at a population level despite the potential for active…
Abstract Number: 203 • 2017 ACR/ARHP Annual Meeting
Intensive Care Unit Admissions Among Patients with Rheumatic Diseases at a Tertiary Care Center
Ali Al-Marzooq¹, Mohammed Al-Charakh¹, Sumediah Nzuonkwelle², Bikash Bhattarai³, Mark McPherson² and Konstantinos Parperis⁴, ¹Internal Medicine, Maricopa Integrated Health System, Phoenix, AZ, ²Maricopa Integrated Health System, Phoenix, AZ, ³Research, Maricopa Integrated Health System, phoenix, AZ, ⁴Rheumatology, Maricopa Integrated Health System and University of Arizona College of Medicine, Phoenix Campus, phoenix, AZ
Background/Purpose: Patients with autoimmune rheumatic diseases have higher risk of developing organ failure and may require admission to intensive care unit (ICU), however there are…
Abstract Number: 2138 • 2017 ACR/ARHP Annual Meeting
Predictive Factors for Achievement of Sustained Remission with Polymyositis/Dermatomyositis: A Retrospective Single Center Cohort Study in Japan
Eri Watanabe¹, Takahisa gono¹, Shinji Watanabe¹, Hiroki Yabe¹, Masataka Kuwana² and Chihiro Terai¹, ¹Department of Rheumatology, Saitama Medical Center, Jichi Medical University, Saitama, Japan, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Polymyositis (PM), dermatomyositis (DM), and clinically amyopathic DM (CADM) are systemic inflammatory diseases that affect skeletal muscle, skin, and other organs, such as lungs,…
Abstract Number: 220 • 2017 ACR/ARHP Annual Meeting
English Language Proficiency and Total Joint Replacement Outcomes: Is There a Relationship?
Bella Y. Mehta¹, Jackie Szymonifka², Shirin A. Dey², Stephen Grassia³, Lisa A. Mandl⁴, Anne R. Bass⁴, Linda A. Russell⁴, Michael L. Parks⁵, Mark P. Figgie⁵, Yuo-Yu Lee⁶, Joseph T. Nguyen⁶ and Susan M. Goodman⁴, ¹Hospital for Special Surgery/Columbia University Mailman School of Public Health, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Medicine, Hospital for Special Surgery, New York, NY, ⁴Rheumatology, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁵Orthopaedic Surgery, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁶Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY
Background/Purpose: Healthcare disparities are recognized for surgical outcomes in patients with Limited English Proficiency (LEP) (1). The purpose of this study is to assess the…
Abstract Number: 2295 • 2017 ACR/ARHP Annual Meeting
Methotrexate As First Line Therapy in Juvenile Idiopathic Arthritis-Associated Uveitis: Myth or Reality
Jacopo Agnolucci¹, Maria Elisabetta Zannin¹, Giorgia Martini¹, Alessandra Meneghel² and Francesco Zulian², ¹Department of Woman and Child Health, University of Padua, Padua, Italy, ²University of Padua, Department of Woman and Child Health, Padua, Italy
Background/Purpose: Methotrexate (MTX) is the most used immunomodulatory drug in Juvenile Idiopathic Arthritis-associated uveitis (JIA-U) although its efficacy has been shown only in retrospective studies…
Abstract Number: 311 • 2017 ACR/ARHP Annual Meeting
Total Ankle Arthroplasty for Rheumatoid Arthritis Cases in This Biologics Era: Mid to Long-Term Follow-up
Makoto Hirao¹, Jun Hashimoto², Hideki Tsuboi³, Kosuke Ebina⁴ and Hideki Yoshikawa⁵, ¹Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Suita, Japan, ²Rheumatology/Orthopaedics, Osaka-Minami Medical Ctr, Kawachinagano, Japan, ³Orthopaedics/Rheumatology, Osaka Rosai Hospital, Sakai, Japan, ⁴Orthopaedics, Osaka University Graduate School of Medicine, Suita, Japan, ⁵Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan
Background/Purpose: Outcomes after total ankle arthroplasty (TAA) combined with additive techniques (augmentation of bone strength, control of soft tissue balance, adjustment of the loading axis)…
Abstract Number: 2314 • 2017 ACR/ARHP Annual Meeting
Monoarticular Juvenile Idiopathic Arthritis: A Unique Entity?
Caterina Politi¹, Vanessa Cecchin¹, Fabio Vittadello¹, Alessandra Meneghel², Giorgia Martini¹ and Francesco Zulian², ¹Department of Woman and Child Health, University of Padua, Padua, Italy, ²University of Padua, Department of Woman and Child Health, Padua, Italy
Background/Purpose: Oligoarticular Juvenile Idiopathic Arthritis (oligoJIA) is the most common JIA subtype. According with the most recent classification criteria1, monoarticular JIA (monoJIA) is included in…
Abstract Number: 1062 • 2016 ACR/ARHP Annual Meeting
Non-Conventional Antiphospholipid Antibodies in Patients with Clinical Obstetrical APS: Prevalence and Pregnancies Treatment Efficacy
ARSENE MEKINIAN¹, Marie Charlotte Bourrienne², LIONEL CARBILLON³, AMELIE BENBARA⁴, SYLVIE CHOLLET MARTIN⁵, AHMED TIGAIZIN³, Francois Montestruc⁶, Olivier Fain⁷ and Pascale Nicaise-Roland⁸, ¹SAINT ANTOINE HOSPITAL, PARIS, France, ²Unité Fonctionnelles d'Immunologie « Autoimmunité et Hypersensibilités », AP-HP, Hôpital Bichat-Claude Bernard, Paris, paris, France, ³JEAN VERDIER HOSPITAL, BONDY, France, ⁴JEAN VERDIER HOSPITAL, PARIS, France, ⁵UNITE HYPERSENSIBILITE, PARIS, France, ⁶exystat, PARis, France, ⁷Internal Medicine Department, Saint Antoine Hospital, Paris, France, ⁸Immunology Department, Bichat Claude-bernard, Universitary Hospital, APHP, Paris, France
Background/Purpose: To describe the prevalence of non-conventional APL in patients with obstetrical APS pregnancy adverse outcome without conventional APL and the impact of treatment on…

« Previous Page
1
…
3
4
5
6
7
…
10
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].